TADALAFIL HEMI PHARMA: Compound Profile
Tadalafil Citrate is a selective phosphodiesterase type 5 (PDE5) inhibitor compound extensively studied in vascular research applications. This research chemical from Hemi Pharma provides investigators with access to a well-characterised compound for examining cyclic guanosine monophosphate (cGMP) pathways and smooth muscle physiology. Research teams at Stroid UK Shop select this compound for investigating nitric oxide signalling cascades and endothelial function studies. Tadalafil demonstrates selectivity for PDE5 over other phosphodiesterase isoforms, making it valuable for targeted enzymatic research protocols.
Laboratory Applications
Investigators utilise this PDE5 inhibitor to examine vascular smooth muscle relaxation mechanisms and blood flow regulation pathways in laboratory models. Research applications include studying pulmonary arterial hypertension models, investigating benign prostatic hyperplasia mechanisms, and analysing erectile dysfunction pathways. The compound’s extended half-life compared to other PDE5 inhibitors allows for sustained experimental protocols. Researchers examining cardiovascular physiology often compare this compound with other modulators available in our erection drugs category. Studies frequently investigate its effects alongside selective androgen receptor modulators and peptide compounds to understand comprehensive physiological responses.
Compound Specifications
| Parameter | Specification |
|---|---|
| Chemical Name | Tadalafil Citrate |
| CAS Number | 171596-29-5 |
| Molecular Formula | C₂₂H₁₉N₃O₄ · C₆H₈O₇ |
| Molecular Weight | 581.55 g/mol |
| Storage Conditions | Room temperature, dry environment |
| Solubility | DMSO, ethanol (verify experimentally) |
Research Use Compliance
This tadalafil citrate product is manufactured by Hemi Pharma exclusively for in-vitro research applications and laboratory studies. This compound is not intended for human consumption, therapeutic use, or any application outside controlled research environments. Researchers must ensure proper laboratory safety protocols and institutional approval before conducting studies with this phosphodiesterase inhibitor compound.
